Theravance Biopharma, Inc.
TBPH
$18.43
-$1.18-6.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 80.33M | 77.21M | 65.27M | 64.38M | 63.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.33M | 77.21M | 65.27M | 64.38M | 63.19M |
| Cost of Revenue | 39.51M | 40.66M | 40.13M | 37.64M | 36.50M |
| Gross Profit | 40.82M | 36.54M | 25.14M | 26.74M | 26.69M |
| SG&A Expenses | 73.63M | 72.18M | 70.80M | 69.17M | 66.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.14M | 112.84M | 110.93M | 106.82M | 103.03M |
| Operating Income | -32.81M | -35.63M | -45.66M | -42.44M | -39.83M |
| Income Before Tax | 47.24M | 40.08M | -48.35M | -44.61M | -40.69M |
| Income Tax Expenses | 17.90M | 27.05M | 9.98M | 11.80M | 8.71M |
| Earnings from Continuing Operations | 29.34 | 13.03 | -58.33 | -56.42 | -49.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.34M | 13.03M | -58.33M | -56.42M | -49.40M |
| EBIT | -32.81M | -35.63M | -45.66M | -42.44M | -39.83M |
| EBITDA | -31.17M | -33.96M | -43.97M | -40.73M | -38.15M |
| EPS Basic | 0.58 | 0.25 | -1.19 | -1.15 | -1.01 |
| Normalized Basic EPS | 0.59 | 0.51 | -0.56 | -0.51 | -0.47 |
| EPS Diluted | 0.56 | 0.23 | -1.19 | -1.16 | -1.01 |
| Normalized Diluted EPS | 0.58 | 0.50 | -0.56 | -0.51 | -0.47 |
| Average Basic Shares Outstanding | 199.71M | 198.23M | 196.80M | 195.37M | 195.48M |
| Average Diluted Shares Outstanding | 201.65M | 198.78M | 196.80M | 195.37M | 195.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |